bioMerieux (OTCMKTS:BMXMF) Stock Rated “Reduce” by Wall Street Brokerages

bioMerieux (OTCMKTS:BMXMF) has been assigned a consensus recommendation of “Reduce” from the six research firms that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation and five have given a hold recommendation to the company.

Several research analysts have recently weighed in on the company. Zacks Research upgraded bioMerieux from a “strong sell” rating to a “hold” rating in a research note on Monday, September 28th. Morgan Stanley reaffirmed an “underweight” rating on shares of bioMerieux in a report on Friday, September 11th.

bioMerieux Price Performance

Shares of BMXMF stock opened at $99.63 on Monday. bioMerieux has a one year low of $77.00 and a one year high of $132.05. The company’s 50-day moving average is $88.01 and its 200 day moving average is $85.98.

About bioMerieux

bioMérieux is a France-based company specializing in in vitro diagnostics. It develops and manufactures diagnostic systems, reagents, software and services used to detect disease, identify infectious organisms and support treatment decisions. Its offerings serve hospitals, clinical laboratories and other healthcare providers, with a particular focus on infectious diseases, antimicrobial resistance and syndromic testing.

The company also provides industrial microbiology solutions for applications such as food safety, pharmaceutical manufacturing and quality control.